PP
ITCI

PFS Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

PFS Partners’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-300
Closed -$39.6K – 525
2025
Q1 		$39.6K Hold
300
– – 0.02% 162
2024
Q4 		$25.1K Hold
300
– – 0.01% 200
2024
Q3 		$22K Hold
300
– – 0.01% 208
2024
Q2 		$20.5K Hold
300
– – 0.01% 197
2024
Q1 		$20.8K Sell
300
-212
-41% -$14.6K 0.01% 198
2023
Q4 		$36.7K Hold
512
– – 0.03% 143
2023
Q3 		$26.7K Hold
512
– – 0.02% 155
2023
Q2 		$32.4K Hold
512
– – 0.03% 146
2023
Q1 		$27.7K Hold
512
– – 0.03% 136
2022
Q4 		$27.1K Hold
512
– – 0.03% 133
2022
Q3 		$23.8K Hold
512
– – 0.03% 128
2022
Q2 		$29.2K Hold
512
– – 0.03% 114
2022
Q1 		$31.3K Hold
512
– – 0.03% 125
2021
Q4 		$26.8K Buy
+512
New +$21.5K 0.02% 140

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

PFS Partners's ITCI Position: Q2 2025 in Review

PFS Partners sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 300 shares — an estimated $39.6K sold.

PFS Partners first reported a position in ITCI in Q4 2021 and held it in 14 quarters. The position peaked at $39.6K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • PFS Partners reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • PFS Partners sold 300 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $39.6K.
  • PFS Partners first reported a position in Intra-Cellular Therapies Inc. in Q4 2021 and held it in 14 quarters.
  • PFS Partners's Intra-Cellular Therapies Inc. position peaked at $39.6K in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on PFS Partners's 13F filing for Q2 2025, filed 16 Jul 2025.